| Biomarker ID | 789 |
| PMID | 22024423 |
| Year | 2011 |
| Biomarker | tPSA |
| Biomarker Basis | Concentration Based(ng/ml) |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include :-ID regulation of gene expression,Prostate cancer, Androgen receptor proteolysis and transcription regulation, Androgen receptor signaling, proteolysis, and transcription regulation, Insulin-like growth factor (IGF) activity regulation by insulin-like growth factor binding proteins (IGFBPs) |
| Experiment | PCa VS Benign Prostatic Hyperplasia |
| Type of Biomarker | Diagnostic |
| Cohort | 442 patients were chosen such that 131 had prostate cancer and 311 had benign prostatic hyperplasia |
| Senstivity | NA |
| Specificity | NA |
| AUC | Whole dataset: [0.786], tPSA range (0-3.9ng/ml) [0.786]; tPSA range (4-10ng/ml) [0.621]; tPSA range (0-10ng/ml) [0.675]; tPSA range (>10ng/ml) [0.730]; |
| Accuracy | NA |
| Level Of Significance | p≤ 0.05 |
| Method Used | Assays |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Independent Patient Cohort |
| Technical Name | KLK3 |